“Guided by input from the Angelman community, REVEAL was intentionally designed to evaluate obudanersen across a broad range of people living with Angelman syndrome, reflecting the real-world diversity of this condition. We are deeply grateful to the entire Angelman syndrome community, especially the participants and their families, whose partnership made this achievement possible.” – Holly Kordasiewicz, Ph.D., executive vice president, chief development officer, Ionis.
Individuals enrolled in REVEAL are assigned to study “Cohorts” based on their age.
Individuals aged 2 – <18 years old are assigned to Cohort 1
Individuals aged 18 – ≤50 years old are assigned to Cohort 2.
While enrollment in Cohort 1 has been completed, participating sites continue to screen participants for Cohort 2.
Individuals interested in learning more about participating in a clinical trial should speak with their doctor. Additional information about REVEAL is available online at https://clinicaltrials.gov/study/NCT06914609.